文献速递胸部肿瘤

IV期非小细胞肺癌局部胸部手术的结局:基于SEER的分析

Outcomes of local thoracic surgery in patients with stage IV non-small-cell lung cancer: A SEER-based analysis.
PubMed 文献 · Eur J Cancer · 2020-12-31

该研究基于SEER数据库1975至2016年90,982例IV期非小细胞肺癌患者,采用倾向性评分匹配等多种统计分析评估局部胸部手术的生存结局。匹配分析显示,手术较非手术、手术联合化疗较单纯化疗、手术联合放化疗较单纯放化疗均改善总生存(中位生存期分别为15 vs 8个月、19 vs 11个月、18 vs 11个月,均P<0.001)。结论提示T1-4、N0-3、转移部位0-1且腺癌或鳞癌的IV期患者可从局部胸部手术联合化疗或放化疗中获益。

要点

  • IV期NSCLC接受局部胸部手术者中位生存期15个月,优于非手术的8个月(P<0.001)。
  • 手术联合化疗较单纯化疗延长中位生存期(19 vs 11个月,P<0.001)。
  • T1-4、N0-3、转移部位0-1的腺癌或鳞癌患者最适合手术联合治疗。

核心结论

  • IV期NSCLC中T1-4、N0-3、转移部位0-1且为腺癌或鳞癌的患者,接受局部胸部手术联合化疗或放化疗后总生存期更长。

研究设计与样本

  • 基于美国国立癌症研究所SEER数据库的回顾性分析,纳入1975至2016年诊断的90,982例IV期NSCLC患者,采用倾向性评分匹配等多种统计方法评估总生存。

主要发现

  • 倾向性评分匹配分析显示,手术较非手术改善总生存(中位生存期15 vs 8个月,P<0.001)。
  • 手术联合化疗较单纯化疗改善总生存(中位生存期19 vs 11个月,P<0.001)。
  • 手术联合放化疗较单纯放化疗改善总生存(中位生存期18 vs 11个月,P<0.001)。
  • 对生存≥1年和≥3年的长期生存者进行序贯landmark分析,单因素和多因素分析均显示上述三种手术相关治疗模式较相应无手术模式改善总生存(P<0.001)。
  • 同步比较不同治疗模式时,手术联合化疗中位生存期22个月,手术联合放化疗18个月,化疗10个月,仅手术9个月,放化疗9个月,手术联合放疗6个月,仅放疗2个月。

关键数值与推荐

  • 亚组分析显示,局部胸部手术联合化疗(对比化疗)或联合放化疗(对比放化疗)带来的总生存获益见于T0-3、N0-2和转移部位0-1的肿瘤亚组。
  • 上述两种治疗模式比较提示,最适合手术的患者为T1-4、N0-3、转移部位0-1且为腺癌或鳞癌的任何组合。

临床怎么用

  • 对IV期NSCLC中T1-4、N0-3、转移部位0-1且病理为腺癌或鳞癌的患者,可考虑局部胸部手术联合化疗或放化疗以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The outcomes of thoracic surgery for patients with stage IV non-small-cell lung cancer (NSCLC) are controversial and uncertain. PATIENTS AND METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results was queried for patients with stage IV NSCLC, including those treated with surgery-participated therapy modalities. Overall survival (OS) was evaluated using a variety of statistical analyses. RESULTS: The analysis was carried out for 90,982 patients from 1975 to 2016 who had been diagnosed as stage IV NSCLC. Propensity score-matched (PSM) analyses that were well-balanced with all the important confounding covariates revealed improved OS (median survival time [MST]) with patients receiving surgery versus non-surgery (MST: 15 versus 8 months, P < 0.001); undergoing surgery plus chemotherapy versus chemotherapy (MST: 19 versus 11 months, P < 0.001); and having surgery plus chemoradiation versus chemoradiation (MST: 18 versus 11 months, P < 0.001). Sequential landmark analyses for long-term survivors of ≥1 and ≥3 years all indicated improved OS (P < 0.001) on univariate and multivariate analyses for the patients receiving the three surgery-related treatment patterns listed earlier, relative to the corresponding surgery-absent treatment modalities. For synchronous presentations of varied treatment paradigms, surgical intervention significantly led to increased OS (MST, months) benefits following treatment paradigms: surgery plus chemotherapy (22), surgery plus chemoradiation (18), chemotherapy (10), surgery only (9), chemoradiation (9), surgery plus radiation (6) and radiation alone (2). The subgroup analysis demonstrated that the elevated OS associated with local thoracic surgery in addition to chemotherapy (versus chemotherapy) or chemoradiation (versus chemoradiation) fell in the subcategories of T0-3, N0-2 and 0-1 (metastatic sites) tumours. The comparison of the aforementioned two types of treatment patterns indicated that the optimal patients for the surgery were those with any combination of T1-4, N0-3, Msite0-1 and adeno- or squamous carcinoma. CONCLUSIONS: The patients with T1-4, N0-3, Msite0-1 and adeno- or squamous carcinoma of stage IV NSCLC had a longer OS with local thoracic surgery in combination with chemotherapy or chemoradiation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jia J, Guo B, Yang Z, et al. Outcomes of local thoracic surgery in patients with stage IV non-small-cell lung cancer: A SEER-based analysis. Eur J Cancer. 2020. PMID: 33388490. doi:10.1016/j.ejca.2020.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。